Naslov
CD15s EXPRESSION IN DIFFERENT CD44CD24 BREAST CANCER CELL SUBPOPULATIONS AFTER THIENO[2,3-b]PYRIDINE TREATMENT

Autori
Mastelić, Angela ; Režić-Mužinić, Nikolina ; Marijan Sandra ; Markotić, Anita ; Delić, Loredana ; Barker, David ; Reynisson, Jóhannes ; Čikeš Čulić, Vedrana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Book of Abstracts of the Congress of the Croatian Society of Biochemistry and Molecular Biology HDBMB22: From Science to Knowledge / - , 2022, 104-104

Skup
Congress of the Croatian Society of Biochemistry and Molecular Biology: From Science to Knowledge (HDBMB22)

Mjesto i datum
Brela, Hrvatska, 28.09.2022. - 01.10.2022

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
breast cancer, CD44CD24, CD15s

Sažetak
Depending to the extent of CD44/CD24 ratio in breast cancer cells, they are more related to cell proliferation and tumorigenesis then to metastasis. CD44+ CD24- cells are well known as cancer stem cell subpopulation. Recently, three different breast CD44CD24 non-cancer stem cell subpopulations have been described as relevant for cancer proliferation and drug resistance: CD44- CD24+ and CD44- CD24- as epithelial, and CD44+ CD24+ as hybrid cells with both mesenchymal and epithelial features. The aim of this study was to investigate novel anticancer compound 1, 3-amino-5-oxo-N-naphthyl- 5, 6, 7, 8- tetrahydrothieno[2, 3-b]quinoline-2-carboxamide, effect upon expression of CD15s, the ligand that enables cancer cell to metastasize, in three different triple negative breast cancer cell subpopulations. MDA-MB-231 triple negative breast cancer cells were incubated 48 h with compound 1 alone or in combination with paclitaxel. Flow cytometric analysis was performed to detect the number of cells in each subpopulation as well as their CD15s expression and percentage of each CD15s+ subpopulation. Compound 1 decreased the number of CD44- CD24+ cells but without statistical significance (p=0.123). CD44+ CD24+ subpopulation was halved (p=0, 021). Compound 1 lowered CD15s expression only in CD44- CD24+ epithelial cells. Treatment with paclitaxel was without effect. In addition to our previous findings of compound 1 effects in CD44+ CD24- cancer stem cells, this study proved its anticancer effects in CD44+ CD24+ and CD44- CD24+ breast cancer cell subpopulations, superior in relation to paclitaxel.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA